# India Glycols share price today (India Glycols Ltd, NSE: INDIAGLYCO)

> India Glycols share price today: ₹323.75 at the NSE close on 3 November 2026, up 57.9% in a year. India Glycols (NSE: INDIAGLYCO) is worth ₹2,168 crore, trades at a P/E of 6.8 and has closed between ₹171.88 and ₹331.95 over the past 52 weeks. > India Glycols Ltd's share price has risen faster than its earnings: +57.9% in a year, against +17.3% for earnings per share. INDIAGLYCO · Alcoholic Beverages · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/india-glycols-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹323.75 (+57.9% in a year)
- P/E: 6.8× (higher than 91% of the last 9.2 years)
- Revenue (Jun 2026): ₹1,130 Cr (+8.7% on a year ago)
- Profit (Jun 2026): ₹97.0 Cr (+32.9% on a year ago)
- Operating margin: 15.0% (+1.0 points on a year ago)
- ROCE: 12%, FY26
- ROIC: 8.7%, against a 12.0% cost of capital: −3.3 points

The main question: the share price moved +57.9% in a year while yearly earnings per share moved +17.3%. The difference came from the market paying a higher multiple. ## What is the India Glycols share price today? India Glycols Ltd's share price was ₹323.75 at the close on 3 November 2026. It has been rising for 26 weeks. That is 33.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹172 and ₹332, and at that close it sat 95% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 20 weeks in a row. Over the last 11 years the share price moved +3,877% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at India Glycols this quarter? 1. Profit up on a year earlier for 10 quarters in a row In the June 2026 quarter profit was ₹97 crore, +32.9% on a year earlier. 3. Highest quarterly profit in 15 quarters Profit of ₹97 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are India Glycols' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), India Glycols reported revenue of ₹1,130 crore, up 8.7% from ₹1,040 crore a year earlier, and a profit of ₹97.0 crore, up 32.9% from ₹73.0 crore. ### India Glycols results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,130 crore | ₹1,040 crore | +8.7% |
| Profit | ₹97.0 crore | ₹73.0 crore | +32.9% |
| Earnings per share | ₹14.45 | ₹11.81 | +22.4% |
| Operating margin | 15.0% | 14.0% | +1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). India Glycols' management discussed these results on a call held on 14 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the India Glycols share price history? India Glycols closed at ₹323.75 on 3 November 2026, up 57.9% from ₹205.02 a year earlier (31 October 2025) and up 252.9% over five years. Its highest weekly close since March 2016 was ₹331.95 on 16 October 2026. ### India Glycols share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹287.45 | +12.6% |
| 1 month ago · 1 Oct 2026 | ₹298.80 | +8.4% |
| 6 months ago · 30 Apr 2026 | ₹220.42 | +46.9% |
| 1 year ago · 31 Oct 2025 | ₹205.02 | +57.9% |
| 3 years ago · 3 Nov 2023 | ₹75.10 | +331.1% |
| 5 years ago · 4 Nov 2021 | ₹91.75 | +252.9% |
| 10 years ago · 4 Nov 2016 | ₹13.40 | +2,316.0% |
| Earliest and lowest weekly close in our records · 11 Mar 2016 | ₹8.14 | +3,877.3% |
| Highest weekly close since March 2016, also the 52-week high · 16 Oct 2026 | ₹331.95 | −2.5% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹171.88 | +88.4% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on India Glycols? 3 Nov 2026: India Glycols closed at ₹323.75, up 12.6% on the week and up 8.4% on the month. 14 Aug 2026: India Glycols held its results call for April to June 2026. Management guided: FY27 IGL Spirits operating profit above ₹500 crore. ### Earlier

- Our read, 19 Jul 2026: The financial record confirms mix-led operating improvement. Debt repayment is constructive but funded by both equity and internal cash, making dilution and capital return important. - Results for April to June 2026: Revenue up 8.7% and profit up 32.9% on a year earlier. - 23 Mar 2026: ex-date for an interim dividend of ₹7.50 a share. - 12 Aug 2025: Share split: face value cut from ₹10 to ₹5 a share (ex-date). ### Our read of the business

The financial record confirms mix-led operating improvement. Debt repayment is constructive but funded by both equity and internal cash, making dilution and capital return important. Latest quarter: Exit-quarter earnings held up while management focused on debt reduction and mix quality. (Our read after the latest results, written 19 July 2026.)

## What dividend does India Glycols pay? The last was an interim dividend of ₹7.50 a share, ex-date 23 March 2026. ### India Glycols dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 23 Mar 2026 | ₹7.50 | Interim |
| 23 Sep 2025 | ₹5 | Dividend |
| 21 Aug 2024 | ₹8 | Dividend |
| 5 Sep 2023 | ₹7.50 | Dividend |
| 29 Aug 2022 | ₹7.50 | Dividend |
| 16 Sep 2021 | ₹6 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. We do not print a yield for India Glycols: one of its dividend records from the last 12 months could not be read cleanly or matched to today’s share count, and we do not guess. Yes. India Glycols Ltd paid out 17% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 4 November 2026.)

## What did India Glycols management say on the latest results call? On the call for April to June 2026, held on 14 August 2026, India Glycols' management guided: FY27 IGL Spirits operating profit above ₹500 crore. > “We will not necessarily be suppliers to every end consumer across the world, but we will definitely be partners of choice. - Rupark Sarswat”
> CFO, on the call for April to June 2026

### What management guided

- FY27 IGL Spirits volumes to double last year's level; Amrut's three-whisky volumes also planned to double and single-malt volume to exceed 10,000. - FY27 IMFL contribution above 30% of potable Spirits revenue; 3-4 new brands planned toward an all-India footprint. - Chemicals over the next 4-5 years: business approximately ₹2,500 crore and operating profit approximately ₹400 crore. - NH Bio Pharma operating profit of ₹130-160 crore over the next 4-5 years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/143/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 14 August 2026.)

## What could change the India Glycols story? What are the risks? The story gets stronger if specialty growth and spirits margins prove durable while debt falls without further dilution. The story weakens if policy clarity is weak, margins normalize, specialty delivery slips or biopharma remains pressured. ### Each change stops working if

- : Spirits margin contracts as premiumisation, channels or ethanol-cost advantage fade. - : Specialty growth misses the stated ambition or commodity and import pressure overwhelms the mix benefit. - : Debt ceases declining, fresh capital is raised on unfavorable terms, or the planned monetisation slips. ### The main risks

- : Biofuel economics depend on policy progression while industry capacity has caught up with demand. ⚠ estimate
- : The financing stance changed quickly and promoter ownership declined after the equity issue. ✓ fact

(Our read after the latest results, written 19 July 2026.)

## What to watch in India Glycols' next results? When India Glycols reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Demerger effectiveness date and transfer execution - check for a communicated milestone beyond the approved scheme. - What to check (from the call)
- Demerger effectiveness date and transfer execution - check for a communicated milestone beyond the approved scheme. - IGL Spirits operating profit delivery and volume trajectory - check whether launches and deeper penetration sustain the stated full-year framework. - Chemicals performance-chemical contribution - check recovery after Middle East exports, raw-material shortages and freight volatility. - NH Bio Pharma customer conversions and nicotine processing - check sustained growth despite raw-material availability and pricing pressure. ## Which stock lists is India Glycols on? India Glycols is not on any of our India lists this week. ## Is India Glycols profitable? India Glycols Ltd earned ₹97.0 Cr of net profit in the Jun 2026 quarter, +32.9% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹293 Cr. That is 8.6% of the quarter's revenue. The same quarter a year earlier earned ₹73.0 Cr. For the full year, FY26 profit was ₹293 Cr (+26.8% on the year before). Why profit moved: revenue changed +8.7% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +29.5% and revenue +12.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY26-Q4. revenue ₹976 Cr and profit ₹87 Cr as reported. FY27-Q1. revenue ₹1,130 Cr and profit ₹97 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much revenue does India Glycols make, and is it growing? India Glycols Ltd reported ₹1,130 Cr of revenue in the Jun 2026 quarter, +8.7% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 10 years it has grown 6.1% a year on average. The last full year, FY26, came in at ₹4,211 Cr. The last four reported quarters add to ₹4,300 Cr. FY26 revenue was ₹4,211 Cr, +11.8% on the year before. Recent pace: the last four quarters grew +12.1% on average, against 6.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.0%, against +9.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +29.9%, against +32.0% a year (stabilising). FY26-Q4. revenue ₹976 Cr and profit ₹87 Cr as reported. FY27-Q1. revenue ₹1,130 Cr and profit ₹97 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does India Glycols keep? India Glycols Ltd's operating margin was 15.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 4.8% and 15.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +0.6 percentage points on the year while gross margin changed +2.0 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. FY26-Q4. revenue ₹976 Cr and profit ₹87 Cr as reported. FY27-Q1. revenue ₹1,130 Cr and profit ₹97 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## Is India Glycols' profit turning into cash? Over the last 3 years, 225% of India Glycols Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹769 Cr of operating cash against ₹293 Cr of profit. After ₹819 Cr of spending on assets, free cash was −₹50.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 225% of profit came in as cash: the cash cycle got 18 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 5.7× depreciation over three years. The next section checks what that spending is building. ## Where does India Glycols' cash go? India Glycols Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 47 days in FY26, down from 65 days in FY21. It spent ₹2,120 Cr on assets over the last 3 years. Customers take 30 days to pay, and stock sits for 139 days on average. At FY26 sales of ₹4,211 Cr, each day of that cycle ties up about ₹11.5 Cr, so roughly ₹542 Cr is tied up in the business at any time. FY26: customers took 30 days to pay and stock sat for 139 days, about 4.6 months of sales sitting as stock, for a full cycle of 47 days, shorter than FY21's 65. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 139 days. Customers pay about 30 days after that. Suppliers are paid at 123 days. Together that makes the 47-day cycle. Spending on assets: ₹2,120 Cr over the last 3 years, against ₹371 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹37.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is India Glycols' P/E ratio, and how does it compare with its own history? India Glycols Ltd's P/E is 6.8×, near the high end of its own history: higher than 91% of past readings. Its usual P/E (the middle reading) is 3.4×, over 9.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹48.02. Why the multiple is where it is: over the past year earnings per share moved +17.3% while the price moved +57.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +28.7% a year; about +9.0% a year came from earnings growth and about +19.7 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the India Glycols share price assume? Worked out from its price on 20 July 2026, India Glycols Ltd's share price assumed profit growth of about 17.2% a year. Today its P/E is 6.8×, higher than 91% of its own last 9.2 years. This is a one-day reading, taken on 20 July 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the India Glycols business getting better or worse? India Glycols Ltd's business is giving mixed signals. Growth has been steadily positive, but ROCE at 13.3% is below the 15% level needed to call it steady growth. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the India Glycols story, and has it been checked? India Glycols Ltd's story is not scored yet against the checks our research set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Our read, 19 July 2026. What is proven. What is not proven yet. The story gets stronger if specialty growth and spirits margins prove durable while debt falls without further dilution. The story weakens if policy clarity is weak, margins normalize, specialty delivery slips or biopharma remains pressured. What would change our mind. The story gets stronger if specialty growth and spirits margins prove durable while debt falls without further dilution. The story weakens if policy clarity is weak, margins normalize, specialty delivery slips or biopharma remains pressured. The test written in advance. The story gets stronger if specialty growth and spirits margins prove durable while debt falls without further dilution. The story weakens if policy clarity is weak, margins normalize, specialty delivery slips or biopharma remains pressured. Measured by: the thesis as written as stated by the next result. What the company does. The financial record confirms mix-led operating improvement. Debt repayment is constructive but funded by both equity and internal cash, making dilution and capital return important. What the surface reading misses. The surface reading is: Full-year earnings improved with a higher operating margin. The research reads it further: Operating profit rose faster than revenue, supporting mix-led quality improvement rather than pure volume recovery. What the surface reading misses. The surface reading is: Profit grew faster than sales. The research reads it further: The spread supports portfolio improvement but also creates a durability question for current margins. Sources: our stock research file (19 July 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did India Glycols management deliver what it promised? What India Glycols Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Historical EBITDA Margin Recast Without Explanation · 14 August 2026. The May 2026 call reported FY22-FY26 EBITDA margins of 9.6%, 11.9%, 12.9%, 13.9%, and 15.5%. In Aug 2026, management presented a materially higher series of 11%, 13%, 14.2%, 14%, and 16.4%, including a 0.9 percentage-point increase to the already reported FY26 margin, without reconciling the calculation basis or explaining a restatement. This creates a material comparability issue for the stated margin-recovery trajectory and profitability assumptions. Demerger Milestone Delayed and Effective Date Unresolved · 14 August 2026. In May 2026, management expected the NCLT order for the demerger in the first 10 days of June. The Aug 2026 call said the scheme was sanctioned only on 17 July 2026 and that the effective date still had to be communicated, representing a material delay and remaining execution uncertainty. Management nevertheless described the restructuring as on plan without explaining the timing change. Bio-Fuel Blending Goals Revised · 18 May 2026. In the Nov 2025 call, management stated that the government was considering increasing the ethanol blending mandate to 27% after 2026. In the latest May 2026 call, the expansion goal discussed by management has been materially reduced to a range of 21-22%. Biopharma Margin Outlook Contradiction · 18 May 2026. Management consistently guided in the Nov 2025 and Feb 2026 calls that the Nature Biopharma segment would experience a significant margin recovery in Q4 FY26. However, in the latest May 2026 call reporting those results, management admitted that margins remained under pressure despite a volume comeback, contradicting the prior directional profitability guidance. Every quote above is taken word for word from the company’s own earnings calls. ## How much does India Glycols earn on its capital? India Glycols Ltd earned a ROCE of 12% in FY26. That is up from a low of 3% in FY15. Its return on capital used (ROIC) is 3.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 7.0% net margin and 0.65× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.0% net margin × 0.65× asset turnover × 2.22× leverage (assets divided by equity) ≈ 10.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.7% − 12.0% = −3.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does India Glycols have too much debt? India Glycols Ltd has total debt of ₹1,691 Cr against shareholder equity of ₹2,933 Cr as of Jun 2026, so its debt is 0.58× its equity. Year by year, that ratio went from 0.59 in FY22 to 0.58 in FY26. Keep that borrowing in mind when reading the returns on this page. Why this happened. Repayment used both equity and internally generated cash. Lower finance cost is constructive, while the final debt-free objective depends on a future joint-venture transaction. ## What is the India Glycols shareholding pattern? Promoters cut their stake in India Glycols Ltd by 1.4 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 59.6% of the company. Domestic institutions moved +1.1 points over the same period, to 3.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −1.4 points over 8 quarters, to 59.6%; Domestic institutions: +1.1 points over 8 quarters, to 3.1%; Foreign institutions: −0.1 points over 8 quarters, to 2.8%. Why the owners changed: promoters drove it (−1.4 points), with the other side taken by domestic institutions (+1.1 points). They reduced their stake. ## How far is India Glycols from balance-sheet trouble? For India Glycols Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does India Glycols rank in its industry? 70.1 out of 100, rank 2 of 16 in Alcoholic Beverages, with 96% of the evidence available. India Glycols Ltd scores 70.1 out of 100 against the 16 companies it is compared with in Alcoholic Beverages, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.6 + 15.2 + 13.3 + 20 = 70.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is India Glycols compared with? India Glycols ranks 2 of 16 Alcoholic Beverages companies on the 4-Factor Sector Score, with 70.1 out of 100. 1. [Radico Khaitan Ltd](https://www.sectoralpha.in/stocks/radico-khaitan-ltd) RADICO · losing its lead · Most evidence points up · 100% evidence 71.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 15.8% · Profit 73.8% · Operating margin change 4 points · 100% evidence Capital efficiency 22.1/25 · ROCE 24.2% · Operating margin 20% · 100% evidence Valuation 7.0/20 · P/E 68.2× · PEG 1.91 · 100% evidence Relative strength 11.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 20.6% · 1 year 30.5% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 22.1 + 7 + 11.9 = 71.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. India Glycols Ltd this page INDIAGLYCO · breaking out · Most evidence points up · 96% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.6/35 · Revenue 12% · Profit 29.9% · Operating margin change 1 points · 88% evidence Capital efficiency 15.2/25 · ROCE 12.4% · Operating margin 15% · 100% evidence Valuation 13.3/20 · P/E 7× · PEG 0.17 · 100% evidence Relative strength 20.0/20 · Lead over its industry 53.7% · Lead over NIFTY 500 51.8% · 1 year 61.8% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.6 + 15.2 + 13.3 + 20 = 70.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [IFB Agro Industries Ltd](https://www.sectoralpha.in/stocks/ifb-agro-industries-ltd) IFBAGRO · quiet · Evidence leans up · 74% evidence 64.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.2/35 · Revenue 38.9% · Profit 90.3% · Operating margin change 1 points · 88% evidence Capital efficiency 13.2/25 · ROCE 12.7% · Operating margin 8% · 100% evidence Valuation 15.5/20 · P/E 12.8× · PEG 0.33 · 65% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.3% · 1 year -39% · 25% evidence · 0 of 12 weeks ahead Exact sum: 27.2 + 13.2 + 15.5 + 8.4 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [United Spirits Ltd](https://www.sectoralpha.in/stocks/united-spirits-ltd) UNITDSPR · quiet · Evidence leans up · 100% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.7/35 · Revenue 1.1% · Profit 12.9% · Operating margin change -1 points · 100% evidence Capital efficiency 22.6/25 · ROCE 26.4% · Operating margin 20% · 100% evidence Valuation 8.4/20 · P/E 53.5× · PEG 3.56 · 100% evidence Relative strength 9.6/20 · Lead over its industry 2.4% · Lead over NIFTY 500 1.8% · 1 year -6.8% · 100% evidence · 7 of 12 weeks ahead Exact sum: 16.7 + 22.6 + 8.4 + 9.6 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Piccadily Agro Industries Ltd](https://www.sectoralpha.in/stocks/piccadily-agro-industries-ltd) PICCADIL · quiet · Evidence leans up · 74% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 28.5% · Profit 30.6% · Operating margin change -1 points · 88% evidence Capital efficiency 15.8/25 · ROCE 18% · Operating margin 17% · 100% evidence Valuation 11.6/20 · P/E 39.2× · PEG 1.38 · 65% evidence Relative strength 9.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.8% · 1 year -17.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 19.4 + 15.8 + 11.6 + 9.8 = 56.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [G M Breweries Ltd](https://www.sectoralpha.in/stocks/g-m-breweries-ltd) GMBREW · quiet · Evidence leans up · 82% evidence 53.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 20.5% · Profit 21% · Operating margin change -2 points · 95% evidence Capital efficiency 18.4/25 · ROCE 18% · Operating margin 23% · 76% evidence Valuation 12.6/20 · P/E 10.4× · PEG n/a · 50% evidence Relative strength 3.3/20 · Lead over its industry -14.5% · Lead over NIFTY 500 -15.2% · 1 year -35.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19.1 + 18.4 + 12.6 + 3.3 = 53.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Associated Alcohols & Breweries Ltd](https://www.sectoralpha.in/stocks/associated-alcohols-breweries-ltd) ASALCBR · basing · Evidence leans down · 81% evidence 48.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.8/35 · Revenue -5.3% · Profit -4.6% · Operating margin change -3 points · 88% evidence Capital efficiency 15.9/25 · ROCE 18% · Operating margin 11% · 100% evidence Valuation 17.4/20 · P/E 13.1× · PEG 0.96 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -30.3% · 1 year -55.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 7.8 + 15.9 + 17.4 + 7.5 = 48.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Globus Spirits Ltd](https://www.sectoralpha.in/stocks/globus-spirits-ltd) GLOBUSSPR · quiet · Evidence leans down · 83% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.6/35 · Revenue 10.8% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 11.6/25 · ROCE 11.2% · Operating margin 8% · 100% evidence Valuation 10.6/20 · P/E 23× · PEG n/a · 15% evidence Relative strength 1.1/20 · Lead over its industry -22% · Lead over NIFTY 500 -22.5% · 1 year -41.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 24.6 + 11.6 + 10.6 + 1.1 = 47.9 · What this means: Earnings are strong; relative strength in its sector is -22% and the one-year return is -41.3%. 9. [Allied Blenders & Distillers Ltd](https://www.sectoralpha.in/stocks/allied-blenders-distillers-ltd) ABDL · breaking out · Evidence leans down · 93% evidence 47.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.5/35 · Revenue 8.6% · Profit -15.3% · Operating margin change -1 points · 100% evidence Capital efficiency 14.9/25 · ROCE 18.4% · Operating margin 12% · 100% evidence Valuation 4.3/20 · P/E 84.8× · PEG 4.13 · 65% evidence Relative strength 18.1/20 · Lead over its industry 26.7% · Lead over NIFTY 500 25.6% · 1 year 5.5% · 100% evidence · 8 of 12 weeks ahead Exact sum: 10.5 + 14.9 + 4.3 + 18.1 = 47.8 · What this means: Relative strength against the index is 25.6%, and revenue and profit growth are weak. 10. [United Breweries Ltd](https://www.sectoralpha.in/stocks/united-breweries-ltd) UBL · quiet · Evidence leans down · 83% evidence 47.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 7.4% · Profit 31.9% · Operating margin change 4 points · 100% evidence Capital efficiency 10.9/25 · ROCE 10.7% · Operating margin 10% · 100% evidence Valuation 9.0/20 · P/E 71.8× · PEG n/a · 15% evidence Relative strength 5.3/20 · Lead over its industry -14.2% · Lead over NIFTY 500 -14.6% · 1 year -34.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 22.4 + 10.9 + 9 + 5.3 = 47.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Tilaknagar Industries Ltd](https://www.sectoralpha.in/stocks/tilaknagar-industries-ltd) TI · breaking out · Evidence leans down · 90% evidence 44.3 out of 100 Growth Capital Valuation Relative
12. [Asgard Alcobev Ltd](https://www.sectoralpha.in/stocks/asgard-alcobev-ltd) quiet · Evidence leans down · 61% evidence 41.6 out of 100 Growth Capital Valuation Relative
13. [Fratelli Vineyards Ltd](https://www.sectoralpha.in/stocks/fratelli-vineyards-ltd) Too little evidence to rank firmly · 50% evidence 39.9 out of 100 Growth Capital Valuation Relative
14. [Sula Vineyards Ltd](https://www.sectoralpha.in/stocks/sula-vineyards-ltd) SULA · quiet · Most evidence points down · 81% evidence 30.6 out of 100 Growth Capital Valuation Relative
15. [Som Distilleries & Breweries Ltd](https://www.sectoralpha.in/stocks/som-distilleries-breweries-ltd) SDBL · breaking out · Most evidence points down · 68% evidence 30.4 out of 100 Growth Capital Valuation Relative
16. [Jagatjit Industries Ltd](https://www.sectoralpha.in/stocks/jagatjit-industries-ltd) JAGAJITIND · losing its lead · Too little evidence to rank firmly · 49% evidence 45.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Alcoholic Beverages](https://www.sectoralpha.in/sectors/alcoholic-beverages), all 16 compared on one page. ## Which companies are close to India Glycols in size? India Glycols is the 7th largest of 16 Alcoholic Beverages companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Allied Blenders & Distillers, Tilaknagar Industries and Piccadily Agro Industries. Just below it: Globus Spirits, G M Breweries and Som Distilleries & Breweries. ### Alcoholic Beverages companies close in size

1. [Allied Blenders & Distillers Ltd](https://www.sectoralpha.in/stocks/allied-blenders-distillers-ltd) ₹19,531 crore
2. [Tilaknagar Industries Ltd](https://www.sectoralpha.in/stocks/tilaknagar-industries-ltd) ₹11,920 crore
3. [Piccadily Agro Industries Ltd](https://www.sectoralpha.in/stocks/piccadily-agro-industries-ltd) ₹5,504 crore
4. India Glycols Ltd ₹2,223 crore
5. [Globus Spirits Ltd](https://www.sectoralpha.in/stocks/globus-spirits-ltd) ₹2,136 crore
6. [G M Breweries Ltd](https://www.sectoralpha.in/stocks/g-m-breweries-ltd) ₹1,795 crore
7. [Som Distilleries & Breweries Ltd](https://www.sectoralpha.in/stocks/som-distilleries-breweries-ltd) ₹1,506 crore

[All 16 Alcoholic Beverages companies, largest first](https://www.sectoralpha.in/sectors/alcoholic-beverages#all-companies)

### Companies close in size in other industries

1. [Pix Transmission Ltd](https://www.sectoralpha.in/stocks/pix-transmission-ltd) ₹2,229 crore · Rubber Processing/Rubber Products
2. [Somany Ceramics Ltd](https://www.sectoralpha.in/stocks/somany-ceramics-ltd) ₹2,227 crore · Ceramics/Tiles/Sanitaryware
3. India Glycols Ltd ₹2,223 crore
4. [Dhenu Buildcon Infra Ltd](https://www.sectoralpha.in/stocks/dhenu-buildcon-infra-ltd) ₹2,213 crore · NBFC - Others
5. [Rossari Biotech Ltd](https://www.sectoralpha.in/stocks/rossari-biotech-ltd) ₹2,212 crore · Seeds/Tissue Culture/Bio Technology

## What else do people ask about India Glycols? ### What is India Glycols's share price today? India Glycols Ltd's share price is ₹323.75, +57.9% over the past year. The whole company is worth ₹2,168 Cr on the market. In the last 52 weeks it traded between ₹172 to ₹332; today it is 95% of the way up from the low, 33.3% above its 200-day average (as of 3 November 2026). ### What were India Glycols's latest quarterly results? India Glycols Ltd reported revenue of ₹1,130 Cr and net profit of ₹97.0 Cr for the Jun 2026 quarter. Revenue rose 8.7% and profit rose 32.9% compared with a year earlier. Earnings per share were ₹14.45. The operating margin was 15.0%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is India Glycols's market cap? India Glycols Ltd's market capitalisation is ₹2,168 Cr at a share price of ₹323.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is India Glycols performing? India Glycols Ltd's share price has been rising for 26 weeks. In its latest quarter, revenue rose 8.7% and profit rose 32.9% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 20 weeks running (as of 3 November 2026). ### Will India Glycols's share price go up? This page does not forecast India Glycols Ltd's share price. What it shows instead: the share price is ₹323.75, and it has been rising for 26 weeks. Its P/E of 6.8× is higher than 91% of its own last 9 years (as of 3 November 2026). ### Who owns India Glycols? Promoters own 59.6% of India Glycols Ltd, foreign institutions 2.8%, domestic institutions 3.1% and the public 34.5% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 1.4 percentage points over 8 quarters (as of 3 November 2026). ### Where is India Glycols in its business cycle? India Glycols Ltd's FY26 operating margin was 15.0%, against a 13-year range of 4.8% to 15.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 15.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the India Glycols story? The main question: the share price moved +57.9% in a year while yearly earnings per share moved +17.3%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is India Glycols a stock worth studying right now? What the numbers show: India Glycols Ltd's share price has risen faster than its earnings: +57.9% in a year, against +17.3% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a India Glycols share price forecast for 2026? What management itself guided: FY27 IGL Spirits operating profit above ₹500 crore. What would change the story: The story gets stronger if specialty growth and spirits margins prove durable while debt falls without further dilution. The story weakens if policy clarity is weak, margins normalize, specialty delivery slips or biopharma remains pressured. This is research, not advice. We’re not SEBI-registered.